Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma

Wang, Qian; Xu, C.; Wang, Wenxian; Zhang, Yongchang; Li, Ziming; Song, Zhengbo; Wang, Jiandong; Yu, Jinpu; Liu, Jingjing; Zhang, Shirong; Cai, Xiuyu; Li, Wen; Zhan, Ping; Liu, Hongbing; Lv, Tangfeng; Miao, Liyun; Lee, Min; Li, Jiancheng; Liu, Baogang; Yuan, Jingping; Jiang, Zhansheng; Lin, Gen; Chen, Xiaohui; Pu, Xingxiang; Rao, Chuangzhou; Lv, Dongqing; Yu, Zhen; Li, Xiaoyan; Tang, Chuanhao; Zhou, Chengzhi; Zhang, Junping; Guo, Hui; Chu, Qian; Meng, Rui; Li, Xuewen; Wu, Jingxun; Hu, Xiao; Zhou, Jin; Zhu, Zhengfei; Chen, Xiaofeng; Pan, Weiwei; Pang, Fei; Zhang, Wenpan; Jian, Qijie; Wang, Kai; Wang, Liping; Zhu, You‐cai; Gao, Yang; Lin, Xinqing; Cai, Jing; Feng, Huijing; Wang, Lin; Du, Yingying; Wang, Yao; Shi, Xuefei; Niu, Xiaomin; Yuan, Dongmei; Yao, Yanwen; Huang, Jian; Wang, Xiaomin; Zhang, Yinbin; Sun, Ping‐Li; Wang, Hong; Ye, Mingxiang; Wang, Dong; Wang, Zhaofeng; Hao, Yue; Wang, Zhen; Wan, Bing; Lv, Donglai; Yu, Jianwei; Kang, Jin Hyoung; Zhang, Jiatao; Zhang, Chao; Wu, Lei; Shi, Lin; Ye, Leiguang; Wang, Gaoming; Wang, Yina; Gao, Feng; Huang, Jianfei; Wang, Guifang; Wei, Jianguo; Huang, Long; Li, Bihui; Zhang, Zhang; Li, Zhongwu; Liu, Yueping; Li, Yuan; Liu, Zhefeng; Yang, Nong; Wu, Lin; Wang, Qiming; Huang, Wenbin; Hong, Zhuan; Wang, Guansong; Qu, Fengli; Fang, M.; Fang, Yong; Zhu, Xiaodong; Du, Ke; Ji, Jiansong; Shen, Yi; Chen, Jing; Zhang, Yiping; Ma, Shenglin; Lu, Yuanzhi; Song, Yong; Liu, Anwen; Zhong, Wen Zhao; Fang, Wenfeng

doi:10.1111/1759-7714.15022

Cited by 3 publications

(1 citation statement)

References 117 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The diagnosis of mesothelioma can be difficult and is often delayed; it can be suspected with CT-imaging but must be confirmed with a biopsy [3][4][5]. Immunohistochemical markers including Wilms' tumor gene 1 WT-1, cytokeratin CK5/6, calretinin, epithelial membrane antigen (EMA), podoplanin, and mesothelin can confirm the diagnosis [6,7].…”

Section: Introductionmentioning

confidence: 99%

Ki67 Tumor Expression Predicts Treatment Benefit Achieved by Macroscopic Radical Lung-Preserving Surgery in Pleural Mesothelioma—A Retrospective Multicenter Analysis

Hintermair,

Iser,

Varga

et al. 2024

Cancers

View full text Add to dashboard Cite

Pleural mesothelioma (PM), linked to asbestos-induced inflammation, carries a poor prognosis. Therapy ranges from therapy limitation to aggressive multimodality treatment. Given the uncertainty about treatment benefits for patients, this study aimed to assess the role of Ki67 as a prognostic and predictive parameter in PM. Ki67 was measured in the specimens of 70 PM patients (17 female, 53 male) from two centers and correlated to overall survival (OS) and therapy outcome. The median OS was 16.1 months. The level of Ki67 expression was divided into low (≤15%) and high (>15%). A low value of Ki67 expression was associated with a longer OS (Ki67 ≤ 15%: 31.2 (95% CI 6.5–55.8) months vs. Ki67 > 15%: 11.1 (95% CI 7.7–14.6) months, p = 0.012). The 5-year survival represents 22% in the low Ki67 expression group, in contrast to 5% in the high Ki67 expression group. We found a significant interaction term of Ki67 with multimodality treatment (p = 0.031) translating to an OS of 48.1 months in the low expression Ki67 group compared to 24.3 months in the high Ki67 expression group when receiving surgery within multimodality therapy. Therefore, Ki67 stands out as a validated prognostic and, most importantly, novel predictive biomarker for treatment benefits, particularly regarding surgery within multimodality therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Ki67 Tumor Expression Predicts Treatment Benefit Achieved by Macroscopic Radical Lung-Preserving Surgery in Pleural Mesothelioma—A Retrospective Multicenter Analysis

Hintermair,

Iser,

Varga

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

Association Study of Pleural Mesothelioma and Oncogenic Simian Virus 40 in the Crocidolite-Contaminated Area of Dayao County, Yunnan Province, Southwest China

Liu,

Wang,

Chen

et al. 2024

Genetic Testing and Molecular Biomarkers

View full text Add to dashboard Cite

Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma

Wang

et al. 2023

Thoracic Cancer

Self Cite

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is a malignant tumor originating from the pleura, and its incidence has been increasing in recent years. Due to the insidious onset and strong local invasiveness of MPM, most patients are diagnosed in the late stage and early screening and treatment for high‐risk populations are crucial. The treatment of MPM mainly includes surgery, chemotherapy, and radiotherapy. Immunotherapy and electric field therapy have also been applied, leading to further improvements in patient survival. The Mesothelioma Group of the Yangtze River Delta Lung Cancer Cooperation Group (East China LUng caNcer Group, ECLUNG; Youth Committee) developed a national consensus on the clinical diagnosis and treatment of MPM based on existing clinical research evidence and the opinions of national experts. This consensus aims to promote the homogenization and standardization of MPM diagnosis and treatment in China, covering epidemiology, diagnosis, treatment, and follow‐up.

show abstract

Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma

Cited by 3 publications

References 117 publications

Ki67 Tumor Expression Predicts Treatment Benefit Achieved by Macroscopic Radical Lung-Preserving Surgery in Pleural Mesothelioma—A Retrospective Multicenter Analysis

Ki67 Tumor Expression Predicts Treatment Benefit Achieved by Macroscopic Radical Lung-Preserving Surgery in Pleural Mesothelioma—A Retrospective Multicenter Analysis

Association Study of Pleural Mesothelioma and Oncogenic Simian Virus 40 in the Crocidolite-Contaminated Area of Dayao County, Yunnan Province, Southwest China

Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma

Contact Info

Product

Resources

About